

Title	Micelle-based activatable probe for in vivo near-infrared optical imaging of cancer biomolecules.
Author(s)	Shimizu, Yoichi; Temma, Takashi; Hara, Isao; Makino, Akira; Yamahara, Ryo; Ozeki, Ei-Ichi; Ono, Masahiro; Saji, Hideo
Citation	Nanomedicine : nanotechnology, biology, and medicine (2014), 10(1): 187-195
Issue Date	2014-01
URL	http://hdl.handle.net/2433/180295
Right	© 2014 Elsevier Inc.; This is not the published version. Please cite only the published version. この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。
Type	Journal Article
Textversion	author

1 **Micelle-based Activatable Probe for *in vivo* Near-Infrared Optical Imaging of**

2 **Cancer Biomolecules**

3

4 Yoichi Shimizu, Ph.D.^{a,b}, Takashi Temma, Ph.D.^a, Isao Hara, Ph.D.^c, Akira Makino,

5 Ph.D.^a, Ryo Yamahara, Ph.D.^c, Ei-ichi Ozeki, Ph.D.^c, Masahiro Ono, Ph.D.^a, Hideo Saji

6 Ph.D.^{a,*}

7

8 ^a Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical

9 Sciences, Kyoto University, Kyoto, Japan

10 ^b Central Institute of Isotope Science, Hokkaido University, Sapporo, Japan

11 ^c Technology Research Laboratory, Shimadzu Corporation, Kyoto, Japan

12

13 **Short Title**

14 Activatable NIR Probe for Cancer Imaging

15

16 ***Corresponding Author:**

17 Hideo Saji, Ph.D.

18 Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical

1 Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto

2 606-8501, Japan

3 Tel: +81-75-753-4556

4 Fax: +81-75-753-4568

5 E-mail: hsaji@pharm.kyoto-u.ac.jp

6

7 Conflict of interest: No conflict of interest

8

9 Sources of support for the research: Grants-in-Aid for Scientific Research (22791189

10 and 23113509) from the Ministry of Education, Culture, Sports, Science and

11 Technology, Japan, and the New Energy and Industrial Technology Development

12 Organization (NEDO), Japan.

13

14 149 words (Abstract)

15 4551 words (Complete manuscript)

16 42 references

17 5 Figures

18

1 **Abstract**

2 Near-infrared (NIR: 800 - 1,000 nm) fluorescent probes, which activate their
3 fluorescence following interaction with functional biomolecules, are desirable for
4 noninvasive and sensitive tumor diagnosis due to minimal tissue interference. Focusing
5 on bioavailability and applicability, we developed a probe with a self-assembling
6 polymer micelle, a lactosome, encapsulating various quantities of NIR dye (IC7-1). We
7 also conjugated anti-HER2 single chain antibodies to the lactosome surface and
8 examined the probe's capacity to detect HER2 in cells and *in vivo*. Micelles
9 encapsulating 20 mol% IC7-1 (hIC7L) showed 30-fold higher fluorescence (λ_{em} : 858
10 nm) after micelle denaturation compared to aqueous buffer. Furthermore, antibody
11 modification allowed specific activation of the probe (HER2-hIC7L) following
12 internalization by HER2-positive cells, with the probe concentrating in lysosomes.
13 HER2-hIC7L intravenously administered to mice clearly and specifically visualized
14 HER2-positive tumors by *in vivo* optical imaging. These results indicate that
15 HER2-hIC7L is a potential activatable NIR probe for sensitive tumor diagnosis.

16

17 **Key Words:** Lactosome; Polymeric micelle; Near-infrared Fluorescence Imaging;
18 Activatable probe; Molecular imaging

19

1 **Background**

2 Cancer is a major cause of death worldwide owing to vigorous cell growth,
3 invasion, and critical metastasis induced by activation of a variety of biomolecules such
4 as proteases ¹ and growth factors ². Therefore, the *in vivo* detection of such
5 biomolecules, particularly in early disease stages, is important for effective treatment
6 with molecular target drugs ³.

7
8 Noninvasive molecular imaging techniques such as optical imaging, nuclear
9 imaging, and magnetic resonance imaging are useful for disease detection ⁴. Among
10 these, optical imaging techniques have been widely studied and have progressed in the
11 past decade due to their technical convenience, lack of radiation exposure, high spatial
12 and temporal resolutions, and availability of activatable fluorescence probes ⁵. To
13 achieve highly sensitive noninvasive *in vivo* imaging with an optical imaging system,
14 bioavailable fluorescence probes ideally would have excitation and emission
15 wavelengths within near-infrared (NIR) region at the range of 800 - 1,000 nm, which
16 minimizes signal attenuation and autofluorescence by tissues ⁶.

17 In our previous study, we developed a nanocarrier-based NIR probe (IC7-1
18 lactosome; IC7L, Fig. 1C) ⁷ composed of a cyanine dye 'IC7-1' (Fig. 1A) and an

1 amphiphilic polydepsipeptide (Fig. 1B). As expected, IC7L showed suitable optical
2 characteristics for *in vivo* imaging with excitation and emission wavelengths of 830 and
3 858 nm, respectively ⁷, and could visualize tumors *in vivo* with less accumulation in the
4 reticuloendothelial system (RES) ⁷⁻⁹. However, IC7L could not distinguish tumor
5 properties such as expression of biomolecules related to malignancy since the tumor
6 accumulation occurred via the enhanced permeability and retention (EPR) effect.

7 To facilitate tumor biomolecule detection by IC7L, we sought to modify IC7L by
8 two strategies: 1) attachment of a targeting ligand on the surface of IC7L, and 2)
9 introduction of a signal activatable system that can suppress signals from non-targeted
10 tissues (Fig. 1D). To make IC7L an activatable probe, we applied a self-quenching
11 mechanism in which lipophilic dye is encapsulated at high concentrations in the
12 hydrophobic core of the lactosome where it forms self-stacking structures that induce a
13 quenched state. Using this strategy, we expected that the quenched probe would
14 recognize the target-biomolecule, be delivered into the cell following biomolecule
15 internalization, and then be dequenched to emit a fluorescence signal after probe
16 denaturation or metabolism (Fig. 1E). As a target biomolecule, we chose human
17 epidermal growth factor receptor 2 (HER2) due to its high expression in tumors, its
18 close relationship with malignancy ¹⁰, and molecular its therapy applications ¹¹. In

1 addition, since HER2 is internalized after interaction with antibodies and subsequently
2 delivered to lysosomes for degradation ¹², this process can be used to trigger probe
3 dequenching to restore fluorescence emission. Thus, HER2 is a suitable target
4 biomolecule for both probe evaluation and future therapeutic applications.

5

6 In this study, we first prepared lactosomes encapsulating IC7-1 at a variety of
7 concentrations, and evaluated both their quenching and dequenching properties in *in*
8 *vitro* experiments. We found that lactosomes encapsulating 20 mol% IC7-1 functioned
9 as activatable probes, and thus named this activatable probe hIC7L with “h” indicating a
10 high dye concentration. We then conjugated an anti-HER2 single chain antibody on the
11 hydrophilic surface of hIC7L to produce HER2-hIC7L, and evaluated its effectiveness
12 as a targeting activatable NIR probe *in vitro* and *in vivo*. Since we also found that
13 several other cyanine dyes could be used similarly to IC7-1 in this activatable system,
14 we selected hCy5L (lactosome encapsulating 20 mol% Cy5) for microscopic study
15 because the Cy5 fluorescence wavelength was preferable to IC7-1 for our microscopy
16 experiments.

17

1 **Methods**

2 **Preparation of IC7L**

3 All chemicals were commercially available and of the highest purity. The
4 amphiphilic polymer of the lactosome (Fig. 1B, polysarcosine-block-poly-L-lactate
5 (PSar₇₀-block-PLLA₃₀) with glycol capping at the *N*-terminal) was supplied by the
6 Shimadzu Corporation (Kyoto, Japan).

7 IC7L was prepared as previously described ⁷. In brief, PSar₇₀-block-PLLA₃₀ (388
8 nmol) and IC7-1-PLLA₃₀ (3.9 - 97 nmol) dissolved in chloroform (500 μ l) were dripped
9 into a glass test tube. The solvent was removed under reduced pressure to form a thin
10 film on the tube wall. Phosphate buffered saline (PBS, 0.1 M, pH 7.4) was then added to
11 the test tube and heated at 82 °C for 20 min. The resulting aqueous solution was filtered
12 through a 0.20 μ m Acrodisc[®] syringe filter (Pall Corp, East Hills, NY). The IC7L size
13 distribution was measured at 25 °C using a Zetasizer Nano-S90 (Malvern Instruments
14 Ltd., UK).

15 IC7L (1 mg/ml, 100 μ l) with an IC7-1 concentration of 1-20 mol% was incubated
16 in 100 μ l PBS (0.1 M, pH 7.4) with or without sodium dodecyl sulfate (SDS, 5% final
17 concentration) for 30 min at room temperature. After incubation, 2.8 ml PBS was added
18 to the solution and the fluorescence emission spectra were measured with a fluorescence

1 spectrometer (Fluorolog-3, HORIBA Jobin Yvon Inc., Kyoto, Japan) following
2 excitation at 815 nm using a slit width of 5 nm for both excitation and emission
3 measurements. The absorption spectra were measured using a UV-1800 (Shimadzu
4 Corporation, Kyoto, Japan).

5

6 **Preparation of anti-HER2 single chain Fv anchored IC7L (HER2-IC7L)**

7 PSar₅₆-block-PLLA₃₀ without *N*-terminal capping was synthesized as we previously
8 reported ⁸. *N*-terminal uncapped PSar₅₆-block-PLLA₃₀ (100 mg), *N*-succinimidyl
9 3-maleimidopropionate (39.1 mg) and diisopropylethylamine (3.8 mg) were dissolved
10 in 1.5 ml dry DMF and stirred for 7 hr at room temperature. The mixture was then
11 purified on a size exclusion column (Sephadex LH-20, GE Healthcare, U.K.) using
12 DMF as the eluent. The high molecular mass fraction was collected and dried *in vacuo*.
13 Maleimide-PSar-block-PLLA (92mg, 90%); ¹H NMR (DMSO-d₆) δ7.01(d, 2H, J=11.6),
14 5.19(t, 30H, J=7.0), 4.26-3.99(m, 150H), 2.91-2.72(m, 275H), 2.05(s, 3H), 1.46(d, 91H,
15 J=6.8).

16 The maleimide-PSar-block-PLLA (194 nmol), PSar₇₀-block-PLLA₃₀ (194 nmol), and
17 IC7-1-PLLA₃₀ (3.9 nmol for IC7L or 97 nmol for hIC7L) were used to prepare
18 maleimide-IC7L/hIC7L as described above.

1

2 Anti-HER2 single chain Fv (scFv) (4D5 C10) with a cysteine at the C-terminus was a
3 kind gift from CANON Inc. (Tokyo, Japan). Anti-HER2 scFv (300 µg, 100 µl PBS) was
4 added to tris(2-carboxyethyl)phosphine hydrochloride (63.7 µg) and incubated for 2 hr
5 on ice before purification on a size-exclusion column (Sephadex G-50, GE Healthcare,
6 UK) to obtain the reduced form of scFv. Anti-HER2 scFv was then added to
7 maleimide-IC7L/hIC7L (1 mg/1 ml) and incubated for 4 hr on ice with protection from
8 light. After incubation, cysteine-HCl (158 µg) was added and further incubated for 30
9 min on ice. The mixture was then ultracentrifuged in an Amicon[®] ultra-4 Centrifugal
10 Filter Unit (100 kDa-cutoff, Millipore, UK) to obtain HER2-IC7L/hIC7L. The purity
11 was analyzed by size exclusion chromatography using a Superdex 200 10/300 GL
12 column (GE Healthcare, U.K.) equilibrated with PBS at a flow rate of 0.5 ml/min.
13 Absorbance at 215 and 830 nm was used to detect the lactosome and IC7-1, respectively,
14 which confirmed that the absorbance peaks at both wavelengths were detected
15 simultaneously in the high molecular weight fraction. The size distribution of
16 HER2-IC7L was measured at 25 °C using a Zetasizer Nano-S90 and transmission
17 electron microscopy that is described in detail in the supplementary material (Fig. S2).
18 The concentration of anti-HER2 scFv conjugated to IC7L/hIC7L was measured by the

1 bicinchoninic acid (BCA) assay, and then the number (molar ratio) of the anti-HER2
2 scFvs per lactosome was then calculated using the estimated molecular weight values:
3 anti-HER2, scFv, 27 kDa; IC7L, 1,172 kDa; hIC7L, 1,315 kDa. The affinity of
4 HER2-IC7L for HER2/neu was determined by surface plasmon resonance using the
5 ProteOn XPR36 Protein Interaction Array system (BIO-RAD Laboratories, Osaka,
6 Japan) ^{13,14} with recombinant human ErbB2/HER2 Fc chimera immobilized on the
7 sensor chip. The sensorgrams of HER2-IC7L and IC7L were fitted by a bivalent
8 interaction model to obtain dissociation rate constants.

9

10 **Cellular uptake study**

11 NCI-N87 human gastric cells (ATCC, Manassas, VA, USA) (HER2-expressing tumor
12 cells) and SUIT-2 human pancreatic carcinoma cells (Health Science Research
13 Resources Bank, Osaka, Japan) (HER2 low-expressing cells) were cultured in
14 RPMI1640 with 10% fetal bovine serum at 37 °C in a humidified atmosphere
15 containing 5% CO₂ ^{15, 16}. After pre-incubation of cells (2×10^5 cells) overnight in 24
16 well poly-D-lysine-coated dishes (Biocoat, Becton Dickinson), probes (40 µg/1 ml
17 RPMI1640 with 50 µM bovine serum albumin (BSA)) were added to the cells and
18 incubated at 37 °C in a humidified atmosphere containing 5% CO₂. At 1, 3 and 6 hr,

1 cells were washed twice with PBS and fluorescence images of the cells were acquired
2 using a Clairvivo OPT (Shimadzu Corporation, Kyoto, Japan) with a 785 nm laser diode
3 for excitation and a 845/55 nm bandpass filter for emission. After image acquisition,
4 these cells were treated with 0.2 N NaOH and the cell lysate protein concentrations
5 measured by BCA assay. The fluorescence intensity of the cells was analyzed by
6 Clairvivo OPT display software ver. 2.60. The fluorescence intensity of the cells was
7 represented as a ratio to the dosage as follows:

$$8 \quad \text{FI ratio} = \frac{[\text{Fluorescence Intensity of the cells}]}{[\text{Fluorescence Intensity of the probe added to the cells}] \times [\text{Cell lysate (mg protein)}]}$$

9 For the blocking study, NCI-N87 cells (2×10^5 cells) were treated with trastuzumab
10 (4.7 mg/1 ml RPMI1640 with 50 μ M BSA, 1000 mol-fold equivalent of HER2-IC7L)
11 for 15 min and HER2-IC7L (40 μ g) was then added. Subsequent fluorescence
12 measurements were carried out as described above.

13

14 **Preparation of Tumor-bearing mice**

15 Female nude mice (BALB/c nu/nu) supplied by Japan SLC, Inc. (Hamamatsu, Japan)
16 were housed under a 12-h light/12-h dark cycle and given free access to food and water.
17 The animal experiments performed in this study were conducted in accordance with
18 institutional guidelines and approved by the Kyoto University Animal Care Committee,

1 Japan.

2 NCI-N87 cells (5×10^6 cells) suspended in 100 μ l PBS containing 50 % Geltrex
3 (Invitrogen Japan, Tokyo, Japan) were subcutaneously inoculated into the right hind
4 legs of mice (4 week old), and an *in vivo* imaging study was performed after a 4-week
5 growth period. In addition, for evaluation of IC7L encapsulating 20 mol% IC7-1,
6 SUIT-2 cells (5×10^6 cells in 100 μ l PBS containing 50 % Geltrex) were also
7 transplanted to the opposite side 2 weeks after the NCI-N87 transplantation.

8

9 ***In vivo* imaging study**

10 HER2-IC7L or IC7L (2 mg / ml PBS, 100 μ l) were injected into the tumor-bearing
11 mice via the tail vein and NIR fluorescence images were taken using a Clairvivo OPT
12 with a 785 nm laser diode for excitation, and a 845/55 nm bandpass filter for emission.
13 During the imaging process, mice remained on the imaging stage under anesthesia using
14 2.5% isoflurane gas in oxygen (1.5 l / min). Regions of interest (ROI) were designated
15 for the tumor and background (around the neck) on the acquired images to measure
16 fluorescence intensities.

17

18 **Statistics**

1 Data are represented as the mean \pm S.D. Statistical analyses were performed with
2 two-way factorial ANOVA followed by a Tukey-Kramer test. Statistical analyses of the
3 *in vitro* blocking study and *in vivo* study were performed with Bartlett's test followed by
4 the Bonferroni-Holm method. A two-tailed value of $p < 0.05$ was considered to be
5 statistically significant.

6

7

1 **Results**

2 **Probe preparation and determination of optical properties**

3 The fluorescence and absorbance spectra of IC7L with encapsulated IC7-1
4 concentrations varying from 1 to 20 mol% are shown in Fig. 2. The fluorescence of
5 IC7L decreased in PBS with increasing IC7-1 concentrations used for lactosome
6 preparation, and was similar to background levels when the IC7-1 concentration was 20
7 mol% (Fig. 2A). On the other hand, the IC7L fluorescence intensity increased in SDS
8 solution as the IC7-1 concentration increased (Fig. 2B). In fact, IC7L with 20 mol%
9 IC7-1 produced 36.1 ± 5.5 fold higher fluorescence at 848 nm in SDS solution
10 compared to PBS, while IC7L with 1 mol% IC7-1 showed similar fluorescence
11 intensities in both SDS solution and PBS. The absorbance spectra showed a blue-shifted
12 band around 750 nm that increased in intensity as the IC7-1 concentration increased in
13 PBS (Fig. 2C) and decreased in SDS solution (Fig. 2D). Based on this result, for the
14 following study we used IC7L with 1 mol% IC7-1 as an “always-on”-type probe and
15 IC7L with 20 mol% IC7-1 as an “activatable” type probe referred to as “hIC7L”. In
16 addition, as shown in the supplementary material, the lactosome probes encapsulating
17 20 mol% of other cyanine dyes, including IR780 (λ_{em} : 812 nm), IR797 (λ_{em} : 828 nm),
18 Cy5 (λ_{em} : 671 nm) and ICG (λ_{em} : 815 nm) also showed fluorescence activatable

1 properties that were similar to hIC7L (Fig.S1).

2 For the HER2-IC7L/hIC7L preparation, the particle sizes of HER2-IC7L,
3 HER2-hIC7L, IC7L and hIC7L were 31.0 ± 2.7 nm ($n = 3$), 30.0 ± 2.5 nm ($n = 6$), 30.4
4 ± 6.0 nm ($n = 3$) and 30.8 ± 4.7 nm ($n = 6$), respectively. The estimated average molar
5 ratio of anti-HER2-scFvs conjugated to an IC7L or an hIC7L were 5.6 ± 1.8 ($n = 3$) and
6 5.9 ± 0.9 ($n = 6$), respectively. The dissociation constant (K_d) of HER2-hIC7L against
7 HER2 protein was about 0.014 ± 0.012 nM ($n = 4$). On the other hand, hIC7L did not
8 bind to HER2 protein and a K_d value could not be calculated.

9

10 ***In vitro* study**

11 The uptake of probes by NCI-N87 cells (high expression levels of HER2) and
12 SUIT-2 cells (low HER2 expression levels) was examined for 6 hr after administration
13 (Fig. 3 and 4). With HER2-IC7L and IC7L sorted as the always-on probes (Fig. 3), the
14 fluorescence of NCI-N87 cells at 1 hr after HER2-IC7L addition was significantly
15 higher than that of cells treated with IC7L and eventually reached a plateau (Fig. 3A).
16 With the activatable probes HER2-hIC7L and hIC7L (Fig. 4), HER2-hIC7L
17 fluorescence in NCI-N87 cells increased gradually and was significantly higher than the
18 hIC7L fluorescence in the cells 3 hr or more after addition (Fig. 4A). In contrast, probe

1 uptake by SUIT-2 cells (Fig. 3B and 4B) was consistently low for all four probes, and
2 treatment with excess trastuzumab blocked uptake of HER2-hIC7L by NCI-N87 cells to
3 levels that were similar to hIC7L uptake (Fig. 4C). Similar results were obtained with
4 BT-474 and MCF-7 cells, which express high and low levels of HER2, respectively (Fig.
5 S5).

6 The intracellular probe localization was evaluated by fluorescence microscopy
7 using HER2-hCy5L (Cy5 was encapsulated in lactosomes instead of IC7-1), which
8 showed that the fluorescence localization was similar to the distribution of LysoTracker
9 (Fig. S4).

10

11 ***In vivo* imaging study**

12 With the always-on probes, both HER2-IC7L and IC7L visualized NCI-N87 tumors
13 in xenografted mice at 12 and 24 hr post-administration (Fig. 5A). However, there was
14 no significant difference in the images and the calculated tumor-to-background (T/B)
15 ratios between the HER2-IC7L- and IC7L-administered groups during the study
16 duration (Fig. 5C, 1.8 ± 0.2 vs. 1.8 ± 0.1 at 12 hr and 2.0 ± 0.1 vs. 1.9 ± 0.1 at 24 hr). As
17 for the activatable probes, HER2-hIC7L detected the NCI-N87 tumor more clearly at 12
18 and 24 hr post-administration than did hIC7L (Fig. 5B). In addition, the T/B ratios of

1 HER2-hIC7L increased with time and provided higher values than those of hIC7L (Fig.
2 5D, 2.4 ± 0.2 vs. 1.8 ± 0.2 at 12 hr and 2.8 ± 0.2 vs. 2.0 ± 0.3 at 24 hr). Meanwhile, the
3 T/B ratios in the SUIT-2 tumors were unchanged regardless of the probe used (Fig. 5D,
4 2.0 ± 0.2 vs. 2.0 ± 0.2 at 12 hr and 2.2 ± 0.1 vs. 2.2 ± 0.1 at 24 hr). In addition, similar
5 *in vivo* fluorescence images were also obtained in BT-474 (HER2 high expressing cells)
6 and MCF-7 (HER2 low expressing cells) xenografted SCID mice (Fig. S6).

7

1 Discussion

2 In this study, we first showed that the IC7L fluorescence was quenched with
3 increasing concentrations of IC7-1 encapsulated in lactosomes (Fig. 2A). In the
4 absorbance spectra, the peak around 750 nm emerged as the concentration of IC7-1 was
5 higher in the aqueous buffer (Fig. 2C), and indicated the formation of H-dimers¹⁷.
6 Furthermore, in SDS solution, the quenched IC7L fluorescence was dequenched
7 following lactosome degradation and subsequent release of the encapsulated dyes (Fig.
8 2B). Similar results were also obtained with lactosomes that encapsulated other
9 cyanine dyes at a molar ratio of 20 mol% (Fig. S1). Therefore, this quenching would be
10 attributable to the effective stacking of cyanine dye molecules within the hydrophobic
11 core of the lactosome due to the probe's high lipophilicity, and these results indicate that
12 lactosomes carrying 20 mol% of cyanine dyes can serve as activatable fluorescence
13 probes.

14
15 We then prepared HER2-hIC7L as a HER2-specific activatable NIR probe. The
16 particle size of this probe was similar to hIC7L. Considering the smaller size of scFv (5
17 nm)¹⁸ compared with the lactosome (30 nm), the occupied volume of anti-HER2-scFv
18 in HER2-hIC7L was very low (presumed to be only about 2.7%). Therefore, the

1 conjugation of anti-HER2-scFv would have minimal effects on the structural properties
2 of hIC7L. The fluorescence of HER2-hIC7L was recovered in HER2 high expressing
3 cells but not in cells lacking HER2, and the increases in fluorescence ratios for HER2
4 high expressing cells were much higher for HER2-hIC7L than HER2-IC7L. In addition,
5 the fluorescence microscopy using HER2-hCy5L rather than HER2-hIC7L revealed that
6 the HER2-hCy5L fluorescence was localized to the lysosomes 6 hours after treatment
7 (Fig. S4). These *in vitro* studies thus verify the mechanism of fluorescence activation in
8 anti-HER2 scFv-conjugated lactosomes encapsulating high concentrations of cyanine
9 dyes in that: 1) they are targeted to HER2 expressed on the cell surface of tumors, 2) are
10 internalized via interactions with HER2, and finally, 3) probe delivery to and
11 denaturation in the lysosomes relieves quenching, leading to fluorescence recovery.

12
13 Targeting ligands such as antibodies have been widely used in “active targeting
14 systems” for tumor-specific imaging and drug delivery^{19, 20}. Therefore, we first
15 performed an *in vivo* study using anti-HER2-scFv conjugated to the always-on type NIR
16 lactosomes (HER2-IC7L) with the expectation that increased accumulation in tumors
17 induced by active targeting of HER2 would be observed. Unfortunately, there was no
18 difference in tumor fluorescence between HER2-IC7L and IC7L (Fig. 5A, C) and

1 anti-HER2 scFv could not provide beneficial effects for IC7L on HER2-expressing
2 tumor accumulation. These results might be due to a fundamental feature of lactosomes
3 in effective tumor delivery by an EPR effect ^{8,9}, as was also reported in previous works
4 using other nanocarrier probes that showed similar diminished effectiveness of
5 antibodies for tumor targeting ²¹.

6 In contrast, compared to hIC7L, the activatable type HER2-hIC7L clearly
7 visualized tumors expressing high levels of HER2 (Fig. 5B, D, S6). Since an antibody
8 used as a targeting ligand was reportedly effective for increased cellular uptake of a
9 nanocarrier probe in tumor tissue ²¹, anti-HER2 scFv would also likely accelerate the
10 cellular uptake of HER2-hIC7L via interactions with HER2. This could lead to the
11 dequenching of HER2-hIC7L inside tumor cells and provide clearer tumor images than
12 hIC7L, while the total levels of HER2-hIC7L and hIC7L delivered in tumors might be
13 similar with different rates of probe accumulation in intra- and extracellular spaces in
14 tumors.

15 In recent years, other groups also produced studies on micelle-based activatable
16 probe ²² having fluorescence signals that were controlled by a self-quenching
17 mechanism that was similar to our probe. While the probes from the previous studies
18 could visualize tumors *in vivo* by the EPR effect, probe instability remained an unsolved

1 issue for *in vivo* imaging of functional molecules related to tumor malignancy (about
2 60% of dyes were released at 24 hr after incubation in an aqueous solution). We thus
3 employed a strategy wherein IC7-1 conjugated to the hydrophobic polymer of the
4 lactosome (poly-L-lactic acid; PLLA) was encapsulated to form a stable complex in the
5 lactosome core and suppressed release from the micelle ⁷. On this basis, we could
6 achieve target-specificity *in vivo* tumor imaging.

7 In this study we adopted HER2 as a target biomolecule because HER2 is a
8 representative factor in molecular-targeted breast cancer therapy ¹¹ and participates in
9 the signal transmission of growth factors on the cell surface followed by internalization
10 and eventual delivery to lysosomes for degradation ²³. These qualities make HER2
11 suitable for evaluating fluorescence activation strategies using lactosome probes.
12 However, this approach would not be limited to HER2, but could be applied to other
13 biomolecular targets expressed on the tumor cell surface, such as membrane type 1
14 matrix metalloproteinase ^{24, 25}, folate receptors ²⁶, epidermal growth factor receptors ²⁷,
15 and transferrin receptors ²⁸. Therefore, these results would support that hIC7L coupled
16 with antibodies targeting such biomolecules could be promising activatable NIR probes
17 for specific visualization of target biomolecules expressed on tumors *in vivo*. Since
18 optical imaging technologies have been rapidly advancing in terms of both probes and

1 modalities such as NIR endoscopic cameras ⁵ and clinical breast scanners ²⁹ and is
2 expected especially to provide an informative navigation aid for surgery ³⁰, such
3 activatable NIR probes would be clinically powerful tools for the diagnosis of cancer
4 and other diseases.

5

6 While HER2-hIC7L could visualize HER2-expressing tumors both *in vitro* and *in*
7 *vivo*, significant background fluorescence was also seen in the images due to
8 non-specific dequenching of hIC7L, which is in agreement with the observation that
9 quenched hIC7L was gradually dequenched after 24-hour incubation in mice plasma at
10 37 °C (Fig. S3). In addition, nanocarriers with neutral or positive surface charges are
11 known to cause non-specific cell internalization as was reported in *in vitro* studies ^{31,32}.
12 Although the zeta potential of our lactosome probes was estimated to be -5.0 mV, this
13 might not be sufficiently negative to avoid non-specific cellular uptake in tumors,
14 especially during the delayed phase. Therefore, the improvement of *in vivo* stability and
15 the introduction of negative charge on the probe surface should be considered in
16 subsequent refinement of the probes to achieve higher contrast images.

17

18 Compared with other *in vivo* imaging techniques, optical imaging can greatly

1 benefit from activatable probes. Although a variety of activatable optical probes have
2 been developed ⁵, most have excitation and emission spectra in the visible region (400 -
3 700 nm) and only a few lie in the NIR region (800 - 900 nm). For the two major
4 strategies used to control probe fluorescence, photoinduced electron transfer (PeT) and
5 Förster resonance energy transfer (FRET), there have been difficulties in developing
6 NIR activatable probes, which for PeT may be due to the small charge separation
7 between the highest occupied molecular orbital and the lowest unoccupied molecular
8 orbital ^{5, 33}, and for FRET because of the general lack of organic structures having
9 absorption around 900 – 1,000 nm that is required for the regulation of 800 – 900 nm
10 fluorescence ³⁴. Inorganic fluorescence probes such as quantum dots ^{35, 36} and gold
11 nanorods ³⁷ have developed and shown promise in *in vivo* optical imaging; however,
12 they still invoke concerns about heavy metal toxicity ³⁵, though some trials have been
13 performed that avoided this potential toxicity by coating onto the probe surface with
14 biocompatible compounds such as polyethylene glycol ^{38, 39} and glutathione ⁴⁰. In
15 contrast, our probe is bioavailable since the lactosome is composed of the biodegradable
16 materials poly-sarcosine and poly-L-lactic acid ^{41, 42}, and, as with previous reports using
17 lactosomes, showed no acute or transient toxicity in treated mice in all experiments ^{7, 9}.
18 Therefore, hIC7L conjugated with target-specific antibody derivatives appears to be a

1 safe, promising, and widely applicable probe for noninvasive *in vivo* diagnostic
2 techniques used to detect target biomolecules.

3

4 In conclusion, we developed HER2-hIC7L that shows self-quenched fluorescence
5 and specifically interacts with HER2 expressed on tumor cells, followed by the
6 internalization in these cells, whereupon the fluorescence is dequenched after micelle
7 degradation. These results indicate that a targeting ligand such as an antibody-
8 conjugated lactosome that encapsulates high concentrations of IC7-1 would be a useful
9 NIR probe that is applicable for use in noninvasive *in vivo* optical imaging for specific
10 detection of target biomolecules expressed in tumors.

11

1 **References**

- 2 1. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer
3 progression. *Nat Rev Cancer*. 2002;2:161-74.
- 4 2. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor
5 antagonists in the biology and treatment of cancer. *J Clin Oncol*. 2003;21:2787-99.
- 6 3. Gindy ME, Prud'homme RK. Multifunctional nanoparticles for imaging,
7 delivery and targeting in cancer therapy. *Expert Opin Drug Deliv*. 2009;6:865-78.
- 8 4. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. *Nature*.
9 2008;452:580-9.
- 10 5. Kobayashi H, Ogawa M, Alford R, Choyke PL, Urano Y. New strategies for
11 fluorescent probe design in medical diagnostic imaging. *Chem Rev*. 2010;110:2620-40.
- 12 6. Weissleder R. A clearer vision for in vivo imaging. *Nat Biotechnol*.
13 2001;19:316-7.
- 14 7. Shimizu Y, Temma T, Hara I, Yamahara R, Ozeki E, Ono M, et al.
15 Development of novel nanocarrier-based near-infrared optical probes for in vivo tumor
16 imaging. *J Fluoresc*. 2012;22:719-27.
- 17 8. Makino A, Yamahara R, Ozeki E, Kimura S. Preparation of novel polymer
18 assemblies, "lactosome", composed of Poly(L-lactic acid) and poly(sarcosine).
19 *Chemistry Letters*. 2007;36:1220-1.

- 1 9. Makino A, Kizaka-Kondoh S, Yamahara R, Hara I, Kanzaki T, Ozeki E, et al.
2 Near-infrared fluorescence tumor imaging using nanocarrier composed of poly(L-lactic
3 acid)-block-poly(sarcosine) amphiphilic polydepsipeptide. *Biomaterials*.
4 2009;30:5156-60.
- 5 10. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human
6 breast cancer: correlation of relapse and survival with amplification of the HER-2/neu
7 oncogene. *Science*. 1987;235:177-82.
- 8 11. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al.
9 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast
10 cancer that overexpresses HER2. *N Engl J Med*. 2001;344:783-92.
- 11 12. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Coregulation of
12 epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2)
13 levels and locations: quantitative analysis of HER2 overexpression effects. *Cancer Res*.
14 2003;63:1130-7.
- 15 13. Worn A, Pluckthun A. An intrinsically stable antibody scFv fragment can
16 tolerate the loss of both disulfide bonds and fold correctly. *FEBS Lett*.
17 1998;427:357-61.
- 18 14. Bravman T, Bronner V, Lavie K, Notcovich A, Papalia GA, Myszka DG.

- 1 Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36
2 array biosensor. *Anal Biochem.* 2006;358:281-8.
- 3 15. Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK, et al. The growth
4 inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in
5 gastric cancer cell lines. *Cancer Lett.* 2008;272:296-306.
- 6 16. Steinhauser I, Spankuch B, Strebhardt K, Langer K. Trastuzumab-modified
7 nanoparticles: optimisation of preparation and uptake in cancer cells. *Biomaterials.*
8 2006;27:4975-83.
- 9 17. West W, Pearce S. The Dimeric State of Cyanine Dyes. *J Phys Chem.*
10 1965;69:1894-903.
- 11 18. Vigor KL, Kyrtatos PG, Minogue S, Al-Jamal KT, Kogelberg H, Tolner B, et al.
12 Nanoparticles functionalized with recombinant single chain Fv antibody fragments
13 (scFv) for the magnetic resonance imaging of cancer cells. *Biomaterials.*
14 2010;31:1307-15.
- 15 19. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers
16 as an emerging platform for cancer therapy. *Nat Nanotechnol.* 2007;2:751-60.
- 17 20. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging.
18 *Drug Discov Today.* 2003;8:1112-20.

- 1 21. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, et al.
2 Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor
3 localization but does increase internalization in animal models. *Cancer Res.*
4 2006;66:6732-40.
- 5 22. Cho H, Indig GL, Weichert J, Shin HC, Kwon GS. In vivo cancer imaging by
6 poly(ethylene glycol)-b-poly(varepsilon-caprolactone) micelles containing a
7 near-infrared probe. *Nanomedicine.* 2012;8:228-36.
- 8 23. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in
9 breast cancer. *Oncogene.* 2000;19:6102-14.
- 10 24. Osenkowski P, Toth M, Fridman R. Processing, shedding, and endocytosis of
11 membrane type 1-matrix metalloproteinase (MT1-MMP). *J Cell Physiol.*
12 2004;200:2-10.
- 13 25. Shimizu Y, Temma T, Sano K, Ono M, Saji H. Development of membrane
14 type-1 matrix metalloproteinase-specific activatable fluorescent probe for malignant
15 tumor detection. *Cancer Sci.* 2011;102:1897-903.
- 16 26. Leamon CP, Low PS. Delivery of macromolecules into living cells: a method
17 that exploits folate receptor endocytosis. *Proc Natl Acad Sci U S A.* 1991;88:5572-6.
- 18 27. Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ.

- 1 Correlating EGFR expression with receptor-binding properties and internalization of
2 ⁶⁴Cu-DOTA-cetuximab in 5 cervical cancer cell lines. *J Nucl Med.* 2008;49:1472-9.
- 3 28. Hopkins CR, Trowbridge IS. Internalization and processing of transferrin and
4 the transferrin receptor in human carcinoma A431 cells. *J Cell Biol.* 1983;97:508-21.
- 5 29. Tromberg BJ, Cerussi A, Shah N, Compton M, Durkin A, Hsiang D, et al.
6 Imaging in breast cancer: diffuse optics in breast cancer: detecting tumors in
7 pre-menopausal women and monitoring neoadjuvant chemotherapy. *Breast Cancer Res.*
8 2005;7:279-85.
- 9 30. Polom K, Murawa D, Rho YS, Nowaczyk P, Hunerbein M, Murawa P. Current
10 trends and emerging future of indocyanine green usage in surgery and oncology: a
11 literature review. *Cancer.* 2011;117:4812-22.
- 12 31. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-circulating
13 poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated
14 surface charge. *J Control Release.* 2001;77:27-38.
- 15 32. Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, et al. The effect of surface
16 charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles.
17 *Biomaterials.* 2011;32:3435-46.
- 18 33. Koide Y, Urano Y, Hanaoka K, Terai T, Nagano T. Evolution of group 14

1 rhodamines as platforms for near-infrared fluorescence probes utilizing photoinduced
2 electron transfer. *ACS Chem Biol.* 2011;6:600-8.

3 34. Luo S, Zhang E, Su Y, Cheng T, Shi C. A review of NIR dyes in cancer
4 targeting and imaging. *Biomaterials.* 2011;32:7127-38.

5 35. Wang Y, Chen L. Quantum dots, lighting up the research and development of
6 nanomedicine. *Nanomedicine.* 2011;7:385-402.

7 36. Derfus AM, Chan, C.W.C., Bhatia, S.N. Probing the Cytotoxicity of
8 Semiconductor Quantum Dots. *Nano Lett.* 2004;4:11-8.

9 37. Murphy CJ, Gole AM, Stone JW, Sisco PN, Alkilany AM, Goldsmith EC, et al.
10 Gold nanoparticles in biology: beyond toxicity to cellular imaging. *Acc Chem Res.*
11 2008;41:1721-30.

12 38. Papagiannaros A, Levchenko T, Hartner W, Mongayt D, Torchilin V. Quantum
13 dots encapsulated in phospholipid micelles for imaging and quantification of tumors in
14 the near-infrared region. *Nanomedicine.* 2009;5:216-24.

15 39. Hoshino A, Manabe N, Fujioka K, Suzuki K, Yasuhara M, Yamamoto K. Use
16 of fluorescent quantum dot bioconjugates for cellular imaging of immune cells, cell
17 organelle labeling, and nanomedicine: surface modification regulates biological
18 function, including cytotoxicity. *J Artif Organs.* 2007;10:149-57.

1 40. Simpson CA, Salleng KJ, Cliffel DE, Feldheim DL. In vivo toxicity,
2 biodistribution, and clearance of glutathione-coated gold nanoparticles. *Nanomedicine*.
3 2013;9:257-63.

4 41. Gupta B, Revagadea N, Hilbornb J. Poly(lactic acid) fiber: An overview
5 *Progress in Polymer Science*. 2007;32:455-82.

6 42. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor,
7 N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
8 *Biol Psychiatry*. 2004;55:452-6.

9

10

11

1 **Figure Legends**

2 **Figure 1.** Schematic illustration of HER2-hIC7L design and strategy. A: IC7-1 chemical
3 structure. B: Chemical structure of the amphiphilic block polymer of the “lactosome”
4 (PSar-PLLA). C: Schematic illustration of our previously reported probe IC7L
5 (always-on type probe) we previously reported ⁷. IC7L is a lactosome that encapsulates
6 1 mol% IC7-1. D: Schematic illustration of the activatable type probe, HER2-hIC7L,
7 developed in this study. The HER2-hIC7L is a lactosome encapsulating 20 mol% IC7-1
8 with anti-HER2 scFv conjugated to the surface. HER2-hIC7L fluorescence is quenched
9 due to self-quenching of IC7-1 in the hydrophobic core of the lactosome. E: Schematic
10 explanation of the HER2-hIC7L fluorescence signal activation mechanism. Quenched
11 HER2-hIC7L first interacts with HER2 expressed on the tumor, whereupon the probe is
12 internalized, and then dequenched with subsequent probe denaturation.

13

14 **Figure 2.** Optical characteristics of activatable type IC7L. Fluorescence emission (A, B)
15 and absorbance spectra (C, D) of IC7L encapsulating IC7-1 molar ratios ranging from 1
16 (purple), 2.5 (blue), 5 (green), 10 (orange) and 20 mol% (red) after incubation in PBS
17 buffer (A, C) or 5% SDS solution (B, D) for 30 min.

18

1 **Figure 3.** Cellular uptake of always-on type probes. NCI-N87 cells (A) or SUIT-2 cells
2 (B) were treated with HER2-IC7L (bold line) or IC7L (dotted line). Fluorescence
3 intensities were acquired for 6 hr. Data are expressed as the FI Ratio (mean \pm S.D.) for
4 3-4 samples. Comparison between the HER2-IC7L-treated and IC7L-treated groups was
5 performed with two-way factorial ANOVA followed by a Tukey-Kramer test ($*p < 0.05$
6 vs. IC7L).

7
8 **Figure 4.** Cellular uptake of activatable-type probes. NCI-N87 cells (A) and SUIT-2
9 cells (B) were treated with HER2-hIC7L (bold line) or hIC7L (dotted line), and the
10 fluorescence intensities were acquired for 6 hr. For an inhibition study, NCI-N87 cells
11 were pre-treated with 4.7 mg trastuzumab for 15 min and then treated with
12 HER2-hIC7L for 6 hr (C). Data are expressed as the FI Ratio (mean \pm S.D.) for 3-4
13 samples. Comparisons between the HER2-hIC7L-treated and hIC7L-treated groups, and
14 among each concentration of trastuzumab-pretreated HER2-hIC7L and hIC7L addition
15 groups were performed with two-way factorial ANOVA followed by a Tukey-Kramer
16 test ($*p < 0.01$ vs. hIC7L), and with Bartlett's test followed by the Bonferroni-Holm
17 method ($*p < 0.01$ vs. non- trastuzumab-pretreatment HER2-hIC7L), respectively.

18

1 **Figure 5.** *In vivo* imaging studies. A: Fluorescence images of NCI-N87 cell xenografted
2 mice at 0 (immediately after injection), 12, and 24 hr after administration of
3 HER2-IC7L (upper) and IC7L (lower). The yellow arrows indicate the tumor. B:
4 Fluorescence images of NCI-N87 (right hind leg) and SUIT-2 (left hind leg) cell
5 xenografted mice at 0 (just after injection), 12, and 24 hr after administration of
6 HER2-hIC7L (upper) and hIC7L (lower). The yellow and red arrows indicate the HER2
7 high-expressing tumor (NCI-N87) and HER2 low-expressing tumor (SUIT-2),
8 respectively. C,D: NCI-N87 and SUIT-2 tumor-to-background (T/B) fluorescence
9 intensity ratio obtained from the region of interest of the tumor and background (around
10 the neck) in mice administered with HER2-IC7L (red) and IC7L (blue) (C) or
11 HER2-hIC7L (red) and hIC7L (blue) (D). Data are expressed as the T/B ratio (mean \pm
12 S.D.). Comparison of the each group was performed with Bartlett's test followed by the
13 Bonferroni-Holm method ($*p < 0.05$).
14
15






Fig 2.tif

[Click here to download high resolution image](#)




A

NCI-N87 (HER2(+))



B

SUIT-2 (HER2(-))








Fig 5.tif
[Click here to download high resolution image](#)


A



B



C



D

